Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation

Lisa Giulino-Roth, Rosanna Ricafort, Nancy A. Kernan, Trudy N. Small, Tanya M. Trippett, Peter G. Steinherz, Susan E. Prockop, Andromachi Scaradavou, Michelle Chiu, Richard J. O'Reilly, Farid Boulad

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Autologous or allogeneic hematopoietic stem cell transplant (SCT) is often considered in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) but there are limited data on the use of SCT for the treatment of NHL in the pediatric setting. Procedure: To evaluate the role of SCT for children with NHL, we reviewed 36 consecutive pediatric patients with NHL who underwent an allogeneic (n=21) or autologous (n=15) SCT at our institution between 1982 and 2004. Pathologic classification included: lymphoblastic lymphoma (n=12), Burkitt lymphoma (BL) (n=5), diffuse large B-cell lymphoma (n=4), anaplastic large cell lymphoma (ALCL) (n=13), peripheral T cell lymphoma (n=1), and undifferentiated NHL (n=1). Donor source for allogeneic-SCT recipients was an HLA-matched related donor (n=15), a matched unrelated donor (n=4), or a mismatched donor (related n=1; unrelated n=1). Twenty-eight patients (78%) had chemotherapy responsive disease at the time of transplant (either CR or PR). Results: Overall survival (OS) and disease-free survival (DFS) were 55% and 53% with a median follow-up of 9.75 years. Outcomes were similar in patients receiving autologous and allogeneic-SCT (DFS 53% in both groups). Patients with ALCL had a DFS of 76.9%. In contrast, of five patients transplanted for BL, none survived. DFS among patients with chemotherapy sensitive disease was 61%, compared with 25% among patients with relapsed/refractory disease (P=0.019). Conclusions: Allogeneic and autologous SCT offer the prospect of durable, disease-free survival for a significant proportion of pediatric patients with relapsed or refractory NHL. Survival is superior among patients with chemotherapy sensitive disease. Pediatr Blood Cancer 2013;60:2018-2024.

Original languageEnglish (US)
Pages (from-to)2018-2024
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Pediatrics
Transplants
Stem Cells
Disease-Free Survival
Anaplastic Large-Cell Lymphoma
Burkitt Lymphoma
Tissue Donors
Drug Therapy
Peripheral T-Cell Lymphoma
Unrelated Donors
Survival
Lymphoma, Large B-Cell, Diffuse
Hematopoietic Stem Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

  • Allogeneic stem cell transplant
  • Autologous stem cell transplant
  • Non-Hodgkin lymphoma
  • Pediatric

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Giulino-Roth, L., Ricafort, R., Kernan, N. A., Small, T. N., Trippett, T. M., Steinherz, P. G., ... Boulad, F. (2013). Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatric Blood and Cancer, 60(12), 2018-2024. https://doi.org/10.1002/pbc.24722

Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. / Giulino-Roth, Lisa; Ricafort, Rosanna; Kernan, Nancy A.; Small, Trudy N.; Trippett, Tanya M.; Steinherz, Peter G.; Prockop, Susan E.; Scaradavou, Andromachi; Chiu, Michelle; O'Reilly, Richard J.; Boulad, Farid.

In: Pediatric Blood and Cancer, Vol. 60, No. 12, 12.2013, p. 2018-2024.

Research output: Contribution to journalArticle

Giulino-Roth, L, Ricafort, R, Kernan, NA, Small, TN, Trippett, TM, Steinherz, PG, Prockop, SE, Scaradavou, A, Chiu, M, O'Reilly, RJ & Boulad, F 2013, 'Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation', Pediatric Blood and Cancer, vol. 60, no. 12, pp. 2018-2024. https://doi.org/10.1002/pbc.24722
Giulino-Roth, Lisa ; Ricafort, Rosanna ; Kernan, Nancy A. ; Small, Trudy N. ; Trippett, Tanya M. ; Steinherz, Peter G. ; Prockop, Susan E. ; Scaradavou, Andromachi ; Chiu, Michelle ; O'Reilly, Richard J. ; Boulad, Farid. / Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 12. pp. 2018-2024.
@article{55e18a2ae6dc4e34ba7cd63bdf75f2fd,
title = "Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation",
abstract = "Background: Autologous or allogeneic hematopoietic stem cell transplant (SCT) is often considered in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) but there are limited data on the use of SCT for the treatment of NHL in the pediatric setting. Procedure: To evaluate the role of SCT for children with NHL, we reviewed 36 consecutive pediatric patients with NHL who underwent an allogeneic (n=21) or autologous (n=15) SCT at our institution between 1982 and 2004. Pathologic classification included: lymphoblastic lymphoma (n=12), Burkitt lymphoma (BL) (n=5), diffuse large B-cell lymphoma (n=4), anaplastic large cell lymphoma (ALCL) (n=13), peripheral T cell lymphoma (n=1), and undifferentiated NHL (n=1). Donor source for allogeneic-SCT recipients was an HLA-matched related donor (n=15), a matched unrelated donor (n=4), or a mismatched donor (related n=1; unrelated n=1). Twenty-eight patients (78{\%}) had chemotherapy responsive disease at the time of transplant (either CR or PR). Results: Overall survival (OS) and disease-free survival (DFS) were 55{\%} and 53{\%} with a median follow-up of 9.75 years. Outcomes were similar in patients receiving autologous and allogeneic-SCT (DFS 53{\%} in both groups). Patients with ALCL had a DFS of 76.9{\%}. In contrast, of five patients transplanted for BL, none survived. DFS among patients with chemotherapy sensitive disease was 61{\%}, compared with 25{\%} among patients with relapsed/refractory disease (P=0.019). Conclusions: Allogeneic and autologous SCT offer the prospect of durable, disease-free survival for a significant proportion of pediatric patients with relapsed or refractory NHL. Survival is superior among patients with chemotherapy sensitive disease. Pediatr Blood Cancer 2013;60:2018-2024.",
keywords = "Allogeneic stem cell transplant, Autologous stem cell transplant, Non-Hodgkin lymphoma, Pediatric",
author = "Lisa Giulino-Roth and Rosanna Ricafort and Kernan, {Nancy A.} and Small, {Trudy N.} and Trippett, {Tanya M.} and Steinherz, {Peter G.} and Prockop, {Susan E.} and Andromachi Scaradavou and Michelle Chiu and O'Reilly, {Richard J.} and Farid Boulad",
year = "2013",
month = "12",
doi = "10.1002/pbc.24722",
language = "English (US)",
volume = "60",
pages = "2018--2024",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation

AU - Giulino-Roth, Lisa

AU - Ricafort, Rosanna

AU - Kernan, Nancy A.

AU - Small, Trudy N.

AU - Trippett, Tanya M.

AU - Steinherz, Peter G.

AU - Prockop, Susan E.

AU - Scaradavou, Andromachi

AU - Chiu, Michelle

AU - O'Reilly, Richard J.

AU - Boulad, Farid

PY - 2013/12

Y1 - 2013/12

N2 - Background: Autologous or allogeneic hematopoietic stem cell transplant (SCT) is often considered in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) but there are limited data on the use of SCT for the treatment of NHL in the pediatric setting. Procedure: To evaluate the role of SCT for children with NHL, we reviewed 36 consecutive pediatric patients with NHL who underwent an allogeneic (n=21) or autologous (n=15) SCT at our institution between 1982 and 2004. Pathologic classification included: lymphoblastic lymphoma (n=12), Burkitt lymphoma (BL) (n=5), diffuse large B-cell lymphoma (n=4), anaplastic large cell lymphoma (ALCL) (n=13), peripheral T cell lymphoma (n=1), and undifferentiated NHL (n=1). Donor source for allogeneic-SCT recipients was an HLA-matched related donor (n=15), a matched unrelated donor (n=4), or a mismatched donor (related n=1; unrelated n=1). Twenty-eight patients (78%) had chemotherapy responsive disease at the time of transplant (either CR or PR). Results: Overall survival (OS) and disease-free survival (DFS) were 55% and 53% with a median follow-up of 9.75 years. Outcomes were similar in patients receiving autologous and allogeneic-SCT (DFS 53% in both groups). Patients with ALCL had a DFS of 76.9%. In contrast, of five patients transplanted for BL, none survived. DFS among patients with chemotherapy sensitive disease was 61%, compared with 25% among patients with relapsed/refractory disease (P=0.019). Conclusions: Allogeneic and autologous SCT offer the prospect of durable, disease-free survival for a significant proportion of pediatric patients with relapsed or refractory NHL. Survival is superior among patients with chemotherapy sensitive disease. Pediatr Blood Cancer 2013;60:2018-2024.

AB - Background: Autologous or allogeneic hematopoietic stem cell transplant (SCT) is often considered in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) but there are limited data on the use of SCT for the treatment of NHL in the pediatric setting. Procedure: To evaluate the role of SCT for children with NHL, we reviewed 36 consecutive pediatric patients with NHL who underwent an allogeneic (n=21) or autologous (n=15) SCT at our institution between 1982 and 2004. Pathologic classification included: lymphoblastic lymphoma (n=12), Burkitt lymphoma (BL) (n=5), diffuse large B-cell lymphoma (n=4), anaplastic large cell lymphoma (ALCL) (n=13), peripheral T cell lymphoma (n=1), and undifferentiated NHL (n=1). Donor source for allogeneic-SCT recipients was an HLA-matched related donor (n=15), a matched unrelated donor (n=4), or a mismatched donor (related n=1; unrelated n=1). Twenty-eight patients (78%) had chemotherapy responsive disease at the time of transplant (either CR or PR). Results: Overall survival (OS) and disease-free survival (DFS) were 55% and 53% with a median follow-up of 9.75 years. Outcomes were similar in patients receiving autologous and allogeneic-SCT (DFS 53% in both groups). Patients with ALCL had a DFS of 76.9%. In contrast, of five patients transplanted for BL, none survived. DFS among patients with chemotherapy sensitive disease was 61%, compared with 25% among patients with relapsed/refractory disease (P=0.019). Conclusions: Allogeneic and autologous SCT offer the prospect of durable, disease-free survival for a significant proportion of pediatric patients with relapsed or refractory NHL. Survival is superior among patients with chemotherapy sensitive disease. Pediatr Blood Cancer 2013;60:2018-2024.

KW - Allogeneic stem cell transplant

KW - Autologous stem cell transplant

KW - Non-Hodgkin lymphoma

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=84885864526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885864526&partnerID=8YFLogxK

U2 - 10.1002/pbc.24722

DO - 10.1002/pbc.24722

M3 - Article

C2 - 24038967

AN - SCOPUS:84885864526

VL - 60

SP - 2018

EP - 2024

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 12

ER -